Andy Coppage

Director, New Product Commercialization @Alnylam Pharmaceuticals

Global commercial lead for ALN-XDH for the treatment of gout and ALN-KHK for the treatment of T2D • Develop and communicate disease landscape knowledge, including understanding of the treatment paradigm, unmet needs, patient segments and competitors to inform program strategy • Lead strategic commercial projects, either internally or in collaboration with vendors, to guide clinical development and commercialization plans • Provide ad-hoc new product commercialization support for the reminder of Alnylam’s early-stage pipeline including cemdisiran for IgA nephropathy, vutrisiran for Stargardt’s disease and zilebesiran for hypertension • Provide commercial input and analytical support for business development and alliance management activities • Collaborate with R&D colleagues to provide commercial perspective on therapeutic areas of focus and prospective disease areas for emerging targets